Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varlitinib - Array BioPharma/ASLAN Pharmaceuticals

Drug Profile

Varlitinib - Array BioPharma/ASLAN Pharmaceuticals

Alternative Names: ARRY-334543; ARRY-543; ASLAN-001; QBT-01; SPS-4370; VAR; Varlitinib tosylate

Latest Information Update: 07 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; ASLAN Pharmaceuticals; National University Hospital (Singapore)
  • Class Antineoplastics; Diamines; Oxazoles; Quinazolines; Small molecules; Thiazoles
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer; Cholangiocarcinoma; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Biliary cancer
  • Phase II/III Gastric cancer
  • Phase II Breast cancer; Cholangiocarcinoma
  • Phase I/II Liver cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Oct 2019 Updated efficacy and adverse events data from a phase I trial in Solid tumours (Combination therapy, Late-stage disease) presented at the 44th European Society for Medical Oncology (ESMO-2019)
  • 24 Sep 2019 Yonsei University Health System, Severance Hospital plans a phase I/II trial for Gastric cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or later) in South Korea (KCT0003583)
  • 20 Sep 2019 ASLAN Pharmaceuticals intends to submit an NDA in China, USA and other major geographies for Biliary cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top